U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07099391) titled 'A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma' on July 25.
Brief Summary: The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).
Study Start Date: July 24
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Dara-RVd
This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
DRUG: Tec-RVd
This study is a phas...